Drug interactions of new antiretroviral drugs;Interacciones farmacológicas de los nuevos antirretrovirales

Farmacia Hospitalaria

Volumn 35, Issue 1, 2011, Pages 36-43

  Serrano Lopez De Las Hazas J I ^a  

^a HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Antiretroviral therapy; Darunavir; Drug interactions; Etravirine; Maraviroc; Raltegravir; Systematic review

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SYSTEMATIC REVIEW;

EID: 79551513969     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farma.2010.01.018     Document Type: Short Survey

References (29)

1. K. Seden, D. Back, and S. Khoo Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable J Antimicrob Chemother. 64 2009 5 8
2. M.M. De Maat, A. de Boer, C.H. Koks, J.W. Mulder, P.L. Meenhorst, and E.C. van Gorp Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care J Clin Pharm Ther. 29 2004 121 130
3. S. Shah, J. McGowan, B. Opulski, A. Lieblein, and A. Saperstein Identification of Drug Interactions Involving ART in New York City HIV Specialty Clinics 2007 CROI; Poster New York 573
4. S.H. Khoo O121 Drug interactions that really matter. University of Liverpool, Liverpool, UK from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9-13 November 2008 Journal of the International AIDS Society. 11 Suppl 1 2008 O6
5. D.A. Rastegar, A.M. Knight, and J.S. Monolakis Antiretroviral medication errors among hospitalized patients with HIV infection Clin Infect Dis. 43 2006 933 938
6. A. Walubo The role of cytochrome P450 in antiretroviral drug interactions Expert Opin Drug Metab Toxicol. 3 2007 583 598
7. K.C. Brown, S. Paul, and A.D. Kashuba Drug interactions with new and investigational antiretrovirals Clin Pharmacokinet. 48 2009 211 241
8. A. Judith, and M.D. Aberg Drug-Drug Interactions With newer antiretroviral agents Top HIV Med. 16 2008 146 150
9. J.J. Kiser Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV Curr Opin HIV AIDS. 3 2008 330 341
10. M.C. Long, J.R. King, and E.P. Acosta Pharmacologic aspects of new antiretroviral drugs Curr HIV/AIDS Rep. 6 2009 43 50
11. L. Dickinson, S. Khoo, and D. Back Pharmacokinetics and drug-drug interactions of antiretrovirals: An update Antiviral Research 85 2010 176 189
12. S.M. Robertson, S.R. Penzak, and A. Pau Drug interactions in the management of HIV infection: an update Expert Opin Pharmacother. 8 2007 2947 2963
13. J. Moltó, M. Valle, and B. Clotet Pharmacological interactions with darunavir Enferm Infecc Microbiol Clin. 26. Suppl 10 2008 Oct 43 50
14. D. Back, V. Sekar, and R.M. Hoetelmans Darunavir: pharmacokinetics and drug interactions Antivir Ther. 13 2008 1 13
15. Ficha técnica de Prezista® (darunavir). [documento en internet] EMEA. European Medicines Agency. [acceso 1 Junio de 2009] Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/prezista/emea-combined-h707es. pdf
16. Interaccioneshiv.com [base de datos en internet]. Hospital Clínic - IDIBAPS. Barcelona [Acceso 1 Junio 2009]. Disponible en: http://www. interaccioneshiv.com/Buscar.asp
17. http://www. hiv-druginteractions.org/ [base de datos en internet]. University of Liverpool, http://www.hiv-druginteractions.org/ [base de datos en internet]. University of Liverpool. [Acceso 1 Junio 2009]. Disponible en: http://www.hiv-druginteractions.org/frames.asp?drug/drg-main.asp
18. J. Madruga, P. Cahn, and R. Haubrich Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 29 38
19. A. Lazzarin, T. Campbell, and B. Clotet Efficacy an safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patient in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 39 48
20. Ficha técnica de Intelence® (etravirina) [documento en internet] EMEA. European Medicines Agency. [acceso 1 Junio de 2009] Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/intelence/emea-combined- h900es.pdf
21. V. Soriano, and E. Poveda Pharmacokinetics, interactions and mechanism of action of maraviroc Enferm Infecc Microbiol Clin. 26 Suppl 11 2008 Oct 12 16
22. J.M. Emmelkamp, and J.K. Rockstroh CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions - review of the literature Eur J Med Res. 12 2007 Oct 15 409 417
23. Ficha técnica de Celsentri®(maraviroc). [documento en internet] EMEA. European Medicines Agency. [acceso 1 Junio de 2009] Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/celsentri/emea-combined- h811es.pdf
24. Ficha técnica de Isentress®(raltegravir). [documento en internet] EMEA. European Medicines Agency. [acceso 1 Junio de 2009] Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/isentress/emea-combined- h860es.pdf
25. R.W. Falcon, and T.N. Kakuda Drug interactions between HIV protease inhibitors and acid-reducing agents Clin Pharmacokinet. 47 2008 75 89
26. S.M. McCabe, P.F. Smith, Q. Ma, and G.D. Morse Drug interactions between proton pump inhibitors and antiretroviral drugs Expert Opin Drug Metab Toxicol. 3 2007 Apr 197 207
27. E. Pontali Interactions of antiretroviral drugs with anti-infectives and other antiretrovirals Chemotherapy. 53 2007 26 29
28. G.M. Ray Antiretroviral and statin drug-drug interactions Cardiol Rev. 17 2009 Jan-Feb 44 47
29. E.M. Yakiwchuk, M.M. Foisy, and C.A. Hughes Complexity of interactions between voriconazole and antiretroviral agents Ann Pharmacother. 42 2008 698 703